Paper38784367
Ibuprofen Would Be the First-Line Nonsteroidal Anti-inflammatory Drug for Polymyalgia Rheumatica: A Case Series of Five Patients.
Inokuma S and 4 others. Cureus, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Ibuprofen Would Be the First-Line Nonsteroidal Anti-inflammatory Drug for Polymyalgia Rheumatica: A Case Series of Five Patients. Papers, record 38784367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38784367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ibuprofen Would Be the First-Line Nonsteroidal Anti-inflammatory Drug for Polymyalgia Rheumatica: A Case Series of Five Patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28551169 | Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. | Semin Arthritis Rheum | 2017 | https://conductscience.org/library/papers/28551169 | PubMed |
| 2 | 34415462 | Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. | Clin Rheumatol | 2022 | https://conductscience.org/library/papers/34415462 | PubMed |
| 3 | 33135113 | Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study. | Infect Dis Ther | 2021 | https://conductscience.org/library/papers/33135113 | PubMed |
| 4 | 37792612 | Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37792612 | PubMed |
| 5 | 22388996 | 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. | Ann Rheum Dis | 2012 | https://conductscience.org/library/papers/22388996 | PubMed |
| 6 | 29311081 | Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29311081 | PubMed |
| 7 | 26535139 | Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. | RMD Open | 2015 | https://conductscience.org/library/papers/26535139 | PubMed |
| 8 | 30285905 | Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. | J Immunother Cancer | 2018 | https://conductscience.org/library/papers/30285905 | PubMed |
| 9 | 35635433 | Polymyalgia Rheumatica. | Dtsch Arztebl Int | 2022 | https://conductscience.org/library/papers/35635433 | PubMed |
| 10 | 28542719 | Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. | Br J Pharmacol | 2018 | https://conductscience.org/library/papers/28542719 | PubMed |
| 11 | 518143 | An evaluation of criteria for polymyalgia rheumatica. | Ann Rheum Dis | 1979 | https://conductscience.org/library/papers/518143 | PubMed |
| 12 | 31704799 | Meningitis due to non-steroidal anti-inflammatory drugs: an often-overlooked complication of a widely used medication. | BMJ Case Rep | 2019 | https://conductscience.org/library/papers/31704799 | PubMed |
| 13 | 31480261 | Incidence and Prevalence of Polymyalgia Rheumatica (PMR): The Importance of the Epidemiological Context. The Italian Case. | Med Sci (Basel) | 2019 | https://conductscience.org/library/papers/31480261 | PubMed |
| 14 | 36260899 | Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. | Am Fam Physician | 2022 | https://conductscience.org/library/papers/36260899 | PubMed |
| 15 | 30297332 | Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. | Ann Rheum Dis | 2018 | https://conductscience.org/library/papers/30297332 | PubMed |
| 16 | 301730 | Action of nonsteroidal, anti-inflammatory drugs on human and rat peripheral leucocyte migration in vitro. | Ann Rheum Dis | 1977 | https://conductscience.org/library/papers/301730 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 40452706 | Oral Steroid Pulse Therapy for Polymyalgia Rheumatica. | Cureus | 2025 | https://conductscience.org/library/papers/40452706 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38784367
GET https://conductscience.org/api/papers/v1/38784367/authors